Anthony S. Marucci
Founder, President, Chief Executive Officer and Director
Mr. Marucci is a Founder of Celldex and serves as the Company’s President and Chief Executive Officer and as a member of the Board of Directors. Prior to his appointment as President and CEO in 2008, Mr. Marucci served as Vice President, Chief Financial Officer, Treasurer and Secretary of Celldex. Celldex, founded in 2004 as a subsidiary of Medarex (now a part of Bristol-Myers Squibb), was spun out as an independent private company in October 2005 with the asset acquisition of CDX-110 from Alteris Therapeutics and the acquisition of Lorantis Limited (Cambridge, UK). In addition to these acquisitions, Mr. Marucci is also responsible for Celldex’s merger with AVANT Immunotherapeutics completed during the first quarter of 2008 and the acquisition of CuraGen Corporation completed in the third quarter of 2009. He was Treasurer of Medarex from December 1998 to March 2004, where he held a series of senior financial positions. He is a member of the Board of Trustees of BioNJ and also served as its Treasurer through 2010. Mr. Marucci is a member of the Board of the College of Business and Public Management at Kean University. Mr. Marucci received a B.S. in Accounting from Kean University, an MBA from Columbia University and an Executive Master of Healthcare Leadership (EMHL) from Brown University.
Senior Vice President, Corporate Affairs and Administration
Ms. Cavanaugh joined Celldex in August 2012 as Vice President of Investor Relations and Corporate Communications. Prior to joining Celldex, she served from 2007 to 2012 as a Vice President at MacDougall Biomedical Communications, a strategic communications and investor relations firm for the life sciences industry, where she developed and implemented programs for more than 20 biopharmaceutical companies and served as the in-house oncology expert. Ms. Cavanaugh has served in a number of leadership positions in the health care and life sciences industry, including Director of Corporate Communications for Point Therapeutics, an oncology-focused biotech company, and Director of Corporate Communications for Fallon Community Health Plan, a leading Massachusetts managed care organization. She began her health care career at the American Cancer Society, holding various positions providing leadership in physician education, corporate communications, government relations and marketing. She completed her tenure there as Division Communications and Marketing Director for the Mid-South Division, where she was responsible for managing the efforts of marketing and communications staff across six states. Throughout her career, Ms. Cavanaugh has played a leadership role in organizational development and employee relations/communication. Ms. Cavanaugh received her B.A. from the University of New Hampshire.
Senior Vice President, Chief Product Development Officer
Elizabeth Crowley is Senior Vice President, Chief Product Development Officer of Celldex. Ms. Crowley joined Celldex in 2009 as Vice President, Clinical Development. Prior to that, she held several senior level roles at CuraGen Corporation, most recently serving as the Vice President of Development Operations, responsible for strategic and operational development activities of the oncology and oncology supportive care portfolio, regulatory affairs, clinical operations and data management. Ms. Crowley started her career at Bayer Corporation in 1992, holding various positions providing leadership of clinical research and project management prior to completing her tenure there as the Director of Global Study Audit Management, assuring the highest standards for program execution. Ms. Crowley received her BS in Chemistry with a concentration in Business from Boston College.
Thomas Davis, M.D.
Executive Vice President and Chief Medical Officer
Dr. Davis is Executive Vice President and Chief Medical Officer of Celldex. Prior to this appointment in 2014, he was Senior Vice President of Clinical Development and Chief Medical Officer of Celldex. Formerly he was Chief Medical Officer at GenVec and Senior Director of Clinical Science at Medarex. He has supervised clinical efforts in adult hematologic malignancies and marrow transplantation and therapeutic antibodies and vaccines at the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) and worked with Dr. Ron Levy on the development of rituximab and idiotype vaccines at Stanford University. Dr. Davis received his B.A. in Biophysics from Johns Hopkins, M.S. in Physiology and M.D. from Georgetown University, and Oncology training at Stanford University.
Tibor Keler, Ph.D.
Founder, Executive Vice President and Chief Scientific Officer
Dr. Keler is a Founder of Celldex and serves as the Company’s Executive Vice President and Chief Scientific Officer. Prior to this appointment in 2014, he was Senior Vice President and Chief Scientific Officer of Celldex. Celldex, founded in 2004 as a subsidiary of Medarex (Medarex is now a wholly-owned subsidiary of Bristol Myers Squibb), was initially spun out as an independent private company in October 2005 with the asset acquisition of CDX-110 from Alteris Therapeutics, Inc. and the acquisition of Lorantis Limited (Cambridge, UK). Previously, Dr. Keler was Senior Director of Preclinical Development and Principal Scientist at Medarex from September 1993 to March 2004. While at Medarex, he was responsible for the preclinical development of a number of Medarex clinical product candidates. In addition, Dr. Keler was responsible for the development of Celldex's core technology and related products. Dr. Keler received his Ph.D. in Microbiology from the University of Pennsylvania.
Senior Vice President and Chief Financial Officer
Mr. Martin joined Celldex in April 2009 as Director of Financial Reporting, Planning and Analysis and most recently served as Vice President, Finance. Prior to joining Celldex, Mr. Martin served as the Director of Finance and Corporate Compliance for Alseres Pharmaceuticals, where he was responsible for managing the financial and SEC reporting and the annual budget and planning process. Mr. Martin began his career at Ernst & Young, holding various positions prior to completing his tenure as Audit Manager, where he provided audit, review, due diligence and consulting services to public and private companies in the biotechnology, medical device, health care, high technology, manufacturing and consumer product industries. Mr. Martin received an M.B.A. from Boston University, a B.S. from Skidmore College and is a Certified Public Accountant.
Ronald A. Pepin, Ph.D.
Senior Vice President and Chief Business Officer
Dr. Pepin joined Celldex in July 2011 as Senior Vice President and Chief Business Officer. He previously served as Vice President at Shire Pharmaceuticals. From 2000 – 2009, as Senior Vice President, Business Development at Medarex, Inc., he was instrumental in establishing more than forty collaborations with global biopharmaceutical companies. Earlier in his career, he served as Executive Director of External Science and Technology at Bristol-Myers Squibb. Dr. Pepin received his B.A. from Tufts University and his Ph.D. in Genetics from Georgetown University.
Richard Wright, Ph.D.
Senior Vice President and Chief Commercial Officer
Dr. Wright is Senior Vice President and Chief Commercial Officer of Celldex. He joined Celldex in 2012 as Vice President of Commercial Operations. Prior to Celldex, Dr. Wright was Managing Director at Navigant Consulting, where he led a Life Sciences practice focused on commercial strategy for oncology, immunology and rare disease therapies. Previously, Dr. Wright was at Bristol-Myers Squibb, where he held senior leadership roles including Senior Vice President of the U.S. Immunology Business and Vice President and Global Commercial Lead for the Immunology Franchise. At Bristol-Myers Squibb, he was responsible for CTLA4-Ig immunotherapies including the blockbuster drug ORENCIA® and the orphan drug NULOJIX®. In these roles he was charged with setting overall business strategy, commercializing the Company’s broad immunology franchise and managing the U.S. marketing and sales organizations. Dr. Wright began his career at Novartis Pharmaceuticals (Sandoz), where he led research aimed at discovering novel inhibitors of cell migration and metastasis, inhibition of tumor-induced angiogenesis and induction of immune tolerance. At Novartis, he later held several roles in new product commercialization, marketing and salesforce leadership in its Transplant and Immunology Business Unit and was responsible for NEORAL®, SIMULECT®, CERTICAN® and MYFORTIC®. Dr. Wright received his B.S. in Biological Sciences from Rutgers University and his M.S. and Ph.D. in Microbiology and Molecular Genetics from The University of Medicine and Dentistry of New Jersey (Rutgers University). He received an M.B.A. in Marketing and Finance from Columbia University.